COMMENT from

Disposable endoscopes set to disrupt the reusable endoscopes market

The development and implementation of single-use, or disposable, medical devices is becoming more widespread. GlobalData has identified that disposable devices are being increasingly used at the expense of reusable counterparts across most markets and therapy areas.


One of the major reasons for this shift has been to prevent the spread of infectious diseases and to reduce the logistics required to sterilise reusable equipment.


Reasons not to use single-use devices include environmental concerns (minimising the production of waste) and the generally cheaper costs associated with reusable devices.


While the Covid-19 pandemic negatively impacted many medical devices markets in 2020, sales for disposable endoscopes defied this trend and experienced significant year-over-year (YOY) growth.


This is because the use of disposable devices decreases the spread of infectious diseases. For example, YOY sales of Ambu’s disposable aScope bronchoscope increased by 50% in 2020 because there was an increased need for bronchoscopes due to the Covid-19 pandemic.


However, the dramatic rise for disposable bronchoscopes surpassed the increase in sales for reusable endoscopes. GlobalData determined that YOY sales for reusable bronchoscopes increased only 22.5% due to the Covid-19 pandemic. This highlights the utility of disposable scopes during times of high patient volume and turnover.


Sales for Ambu’s aScope disposable bronchoscope are growing at a compound annual growth rate (CAGR) of 124%. Since 2014, there has been a 126-fold increase in sales of these disposable bronchoscopes. In contrast, GlobalData estimates that the global market for reusable bronchoscopes will grow at a rate of only 2.7% over the next ten years.


Additionally, since the launch of Ambu’s aScope disposable rhinoscope in 2019, its sales grew by 441% in 2020 despite the Covid-19 pandemic. A 2017 study conducted by Perbet and colleagues and published in Annals of Intensive Care found that the cost of using Ambu’s single-use aScopes in intensive care units was not significantly higher than that of reusable scopes.


This is because reusable scopes are associated with high costs for repairs and decontamination. This could explain the rapid update for disposable endoscopes at the expense of reusable scopes.


In December 2019, the FDA approved the first fully disposable duodenoscope, Boston Scientific’s EXALT Model D Single-Use Duodenoscope. This scope was granted Breakthrough Device designation, as it was the first and only single-use duodenoscope on the market approved in the US. Ambu launched its aScope disposable duodenoscope in 2020 and plans to release the aScope Duo2 in 2022.


GlobalData estimates the global value for 11 reusable endoscope markets to have been worth $6.76bn in 2020, growing at a CAGR of 7.5%. GlobalData expects the recent and future releases of multiple disposable endoscopes to act as a major disruptor to reusable endoscope markets.


Companies that manufacture reusable endoscopes should expedite R&D related to the ease of re-sterilisation or begin to manufacture disposable endoscopes in order to remain competitive.

For more insight and data, visit GlobalData's Medical Intelligence Centre

10/12/2021 07:56:49
  • Home | High-Tech Mental Health Treatments
  • In this issue
  • Contents
  • Formacoat Company Insight
  • Formacoat
  • PSN Labs
  • Accumold
  • Briefing
  • Industry news
  • Covid-19 executive briefing by GlobalData
  • The medical industry briefing
  • uintent Company Insight
  • uintent
  • Apple Rubber
  • Custom Wire Company Insight
  • Custom Wire
  • Comment
  • Hearing implants market to reach $2.1bn by 2028, post-Covid-19
  • Recent hacks highlight importance of strong cybersecurity
  • Disposable endoscopes set to disrupt the reusable endoscopes market
  • Will Covid-19 tests with EUA need to seek FDA approval once pandemic passes?
  • Covid-19 had a negative impact on general surgery device markets in 2020
  • Desert Platforms Company Insight
  • Desert Platforms
  • Combinostics
  • Duke Empirical Company Insight
  • Duke Empirical
  • In Depth
  • How can AI transform pneumonia diagnosis?
  • Using virtual reality to overcome anxious social avoidance
  • Omar Ahmad: medtech’s quest for post-Covid success in 2021
  • NightWare vs nightmares: the sleep tech app helping break PTSD patterns
  • Just a swipe away: how the NHS plans to offer health records on iPhone
  • Diagnostic imaging: assessing the testicular cancer risk
  • Do AI disease prediction models underestimate risk?
  • Will 2021 be just as challenging as 2020 for medtech notified bodies?
  • HirLan Company Insight
  • HirLan
  • Ergonomics Factory
  • FISBA
  • In Data
  • Deals analysis
  • The medical industry key list
  • Global markets and indices
  • Macro-economic indicators
  • Macro-economic indicators (page 2)
  • Events
  • Next issue
  • Axetris
  • Smiths Interconnect
  • mdi Consultants
  • Omnica